Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)
China · Delayed Price · Currency is CNY 18.70
-0.05 (-0.27%)
At close: Feb 13, 2026
SHE:002932 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 351.2 | 350.01 | 749.49 | 10,530 | 2,830 | 959.1 |
Other Revenue | 0.05 | 0.05 | 0.05 | - | - | - |
| 351.25 | 350.06 | 749.54 | 10,530 | 2,830 | 959.1 | |
Revenue Growth (YoY) | 0.58% | -53.30% | -92.88% | 272.12% | 195.05% | 429.43% |
Cost of Revenue | 262.52 | 217.75 | 309.72 | 3,992 | 707.41 | 209.97 |
Gross Profit | 88.74 | 132.31 | 439.82 | 6,538 | 2,122 | 749.13 |
Selling, General & Admin | 144.64 | 165.41 | 218.97 | 591.45 | 273.23 | 122.84 |
Research & Development | 91.98 | 109.55 | 141.42 | 388.36 | 132.74 | 69.93 |
Other Operating Expenses | 72.7 | 0.82 | 1.41 | 59.79 | 12.8 | 5.53 |
Operating Expenses | 351.69 | 278.62 | 446.93 | 1,403 | 439.59 | 204.57 |
Operating Income | -262.95 | -146.31 | -7.11 | 5,135 | 1,683 | 544.56 |
Interest Expense | -0.94 | -1.28 | -10.5 | -3.42 | -2.11 | -0.65 |
Interest & Investment Income | 135.82 | 144.1 | 124.94 | 52.85 | 12.36 | 6.18 |
Currency Exchange Gain (Loss) | 0.65 | 0.65 | 1.22 | 21.52 | -3.13 | -1.44 |
Other Non Operating Income (Expenses) | 2.03 | -1.37 | -1.23 | -1.35 | -1.08 | -0.39 |
EBT Excluding Unusual Items | -125.4 | -4.22 | 107.31 | 5,205 | 1,689 | 548.26 |
Gain (Loss) on Sale of Investments | -0.05 | 1.74 | 4.59 | 2.76 | - | - |
Gain (Loss) on Sale of Assets | 2.32 | 1.79 | 0.31 | 0.01 | - | 0.15 |
Asset Writedown | -34.87 | -34.87 | -38.02 | -147.03 | - | - |
Other Unusual Items | 107.06 | 67.97 | 65.7 | 15.91 | 5.69 | 8.29 |
Pretax Income | -50.94 | 32.42 | 139.89 | 5,076 | 1,695 | 556.7 |
Income Tax Expense | -2.69 | 5.85 | 70.67 | 695.84 | 247.87 | 81.07 |
Earnings From Continuing Operations | -48.25 | 26.56 | 69.22 | 4,381 | 1,447 | 475.63 |
Minority Interest in Earnings | 55.34 | 47.95 | 5.71 | -172.06 | -33.46 | -6.7 |
Net Income | 7.1 | 74.52 | 74.93 | 4,208 | 1,413 | 468.93 |
Net Income to Common | 7.1 | 74.52 | 74.93 | 4,208 | 1,413 | 468.93 |
Net Income Growth | -32.82% | -0.54% | -98.22% | 197.79% | 201.37% | 1029.25% |
Shares Outstanding (Basic) | 217 | 226 | 227 | 228 | 212 | 209 |
Shares Outstanding (Diluted) | 217 | 226 | 227 | 230 | 212 | 209 |
Shares Change (YoY) | -4.65% | -0.54% | -1.22% | 8.61% | 1.43% | 0.23% |
EPS (Basic) | 0.03 | 0.33 | 0.33 | 18.46 | 6.68 | 2.25 |
EPS (Diluted) | 0.03 | 0.33 | 0.33 | 18.31 | 6.68 | 2.25 |
EPS Growth | -29.55% | - | -98.20% | 174.19% | 197.11% | 1026.62% |
Free Cash Flow | -152.4 | -269.81 | 282.52 | 3,699 | 1,023 | 331.4 |
Free Cash Flow Per Share | -0.70 | -1.20 | 1.24 | 16.09 | 4.84 | 1.59 |
Dividend Per Share | 1.200 | 1.230 | 0.120 | 3.490 | 2.027 | 0.643 |
Dividend Growth | 700.00% | 925.00% | -96.56% | 72.18% | 214.98% | 1898.45% |
Gross Margin | 25.26% | 37.80% | 58.68% | 62.09% | 75.00% | 78.11% |
Operating Margin | -74.86% | -41.80% | -0.95% | 48.77% | 59.47% | 56.78% |
Profit Margin | 2.02% | 21.29% | 10.00% | 39.97% | 49.94% | 48.89% |
Free Cash Flow Margin | -43.39% | -77.08% | 37.69% | 35.13% | 36.17% | 34.55% |
EBITDA | -212.92 | -89.26 | 59.3 | 5,180 | 1,704 | 561.8 |
EBITDA Margin | -60.62% | -25.50% | 7.91% | 49.19% | 60.22% | 58.58% |
D&A For EBITDA | 50.03 | 57.05 | 66.41 | 45.04 | 21.28 | 17.24 |
EBIT | -262.95 | -146.31 | -7.11 | 5,135 | 1,683 | 544.56 |
EBIT Margin | -74.86% | -41.80% | -0.95% | 48.77% | 59.47% | 56.78% |
Effective Tax Rate | - | 18.05% | 50.52% | 13.71% | 14.63% | 14.56% |
Revenue as Reported | 351.25 | 350.06 | 749.54 | 10,530 | 2,830 | 959.1 |
Advertising Expenses | - | 9.87 | 12.13 | 56.66 | 23.94 | 6.97 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.